Drug Profile


Alternative Names: CS-3150; XL-550

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Daiichi Sankyo Company
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension; Hyperaldosteronism; Hypertension
  • Phase II Diabetic nephropathies
  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 01 Dec 2016 Daiichi Sankyo plans a phase I pharmacokinetics trial in Healthy volunteers in Japan (PO) (JapicCTI163452)
  • 28 Nov 2016 Daiichi Sankyo completes a phase I trial in Healthy volunteers in Japan (JapicCTI-163286)
  • 24 Nov 2016 Daiichi Sankyo plans a phase I drug-drug interaction trial in Japan (PO) (JapicCTI163443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top